FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.

"Competing interests JO, NP, KM, DT, PC, JA, MA, EB, EC, DC, MD, CD, SDF, CF, AG, PG, KH, WI, P Kottaridis, MFM, UM, LN, KP, TR, WR, MTS and NS have no conflicts to declare. A Khan declares speakers bureau from Astellas. P Krishnamurthy declares honoraria and speakers bureau from Astellas. ALL declares honoraria from Astella. CC declares consultancy from Astellas and Daiichi-Sankyo. A King declares honoraria from Astellas. SK declares speakers bureau from Astellas. NHR declares honoraria from Astellas. RD declares consultancy with Astellas."

"We thank the clinicians and nurse specialists involved in the care of the patients; Michelle Kleeman and Rosamond Nuamah from the Genomics Facility, NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust for sequencing of FLT3 ITD MRD samples; and Dr Adam Ivey and Dr Tamara J. Luck for assistance and advice in establishing the FLT3 ITD MRD assay. JO was supported by fellowship grants from the Haematology Society of Australia and New Zealand and the RCPA Foundation, and thanks Professor Harry Iland for mentorship and supervision. RD receives laboratory funding from Blood Cancer UK, Cancer Research UK and the National Institute for Health Research."